A growing body of research indicates that DPP4 inhibitors may be beneficial in treating a number of cardiovascular conditions, such as HF, coronary atherosclerosis, calcified aortic valve disease, and hypertension. The gene discussed is DPP4; the disease is coronary atherosclerosis.